What To Know
- “We are thrilled for Chris to join our already high-caliber senior management team at an exciting time for the company as we continue to develop the Revivent TC therapy in the U.
- I am excited to be joining a company that is pioneering the only less-invasive therapy option to treat left ventricular dysfunction caused by a heart attack for congestive heart failure patients.
October 5, 2020
Chris Wolff, a cardiac device veteran, has been appointed Vice President of U.S. Sales for BioVentrix.
Chris Wolff will be responsible for driving enrollment in the ongoing ALIVE Trial studying the Company’s Revivent TC™ Transcatheter Ventricular Enhancement System, which has reimbursement from the Centers for Medicare and Medicaid Services (CMS).
Mr. Wolff brings over 20 years of experience in sales, strategy, clinical training, and business development in medical device companies specializing in cardiac devices. Most recently, he served as the Senior National Director of Sales for the Medtronic Inc. (MDT) Mechanical Circulatory Support (MCS) business, where he successfully led commercialization efforts for the HeartWare™ HVAD™ System in the U.S. Prior to Medtronic’s $1.1 billion acquisition of the company in 2016, he served in senior sales positions for HeartWare International, Inc. (HTWR) for four years, where he achieved significant revenue growth that was instrumental to the deal.
“We are thrilled for Chris to join our already high-caliber senior management team at an exciting time for the company as we continue to develop the Revivent TC therapy in the U.S. market,” said Kenneth Miller, President and Chief Executive Officer of BioVentrix, Inc. “His proven track record of spurring adoption for innovative cardiac devices will be invaluable as we focus on completing enrollment in our U.S. pivotal trial.”
Mr. Wolff stated, “Heart failure is a debilitating disease, and more innovative interventions are needed to help manage patients along the continuum of care. I am excited to be joining a company that is pioneering the only less-invasive therapy option to treat left ventricular dysfunction caused by a heart attack for congestive heart failure patients. I look forward to working with the BioVentrix team to drive procedural growth and bring this life-saving technology to patients in need.”
